Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
261M
-
Number of holders
-
61
-
Total 13F shares, excl. options
-
130M
-
Shares change
-
+116M
-
Total reported value, excl. options
-
$410M
-
Value change
-
+$376M
-
Put/Call ratio
-
0.41
-
Number of buys
-
46
-
Number of sells
-
-16
-
Price
-
$3.16
Significant Holders of Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) as of Q3 2023
75 filings reported holding TSHA - Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share as of Q3 2023.
Taysha Gene Therapies, Inc. - Common Stock, $0.00001 par value per share (TSHA) has 61 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 130M shares
of 261M outstanding shares and own 49.71% of the company stock.
Largest 10 shareholders include FMR LLC (24.5M shares), RA CAPITAL MANAGEMENT, L.P. (18.5M shares), RTW INVESTMENTS, LP (16.9M shares), VR Adviser, LLC (14.4M shares), TCG Crossover Management, LLC (11.1M shares), VANGUARD GROUP INC (5.33M shares), Avoro Capital Advisors LLC (3.93M shares), ACUTA CAPITAL PARTNERS, LLC (3.83M shares), Artal Group S.A. (3.66M shares), and Kynam Capital Management, LP (3.28M shares).
This table shows the top 61 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.